methadone has been researched along with buprenorphine, naloxone drug combination in 108 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.93) | 29.6817 |
| 2010's | 65 (60.19) | 24.3611 |
| 2020's | 42 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Guffens, JM | 1 |
| Altice, FL; Chen, S; Springer, SA | 1 |
| Bean, HK; Gannon, R | 1 |
| Degenhardt, L; Dietze, P; Horyniak, D; Larance, B; Winstock, A | 1 |
| Botsko, M; Chaudhry, AA; Egan, JE; Estrada, B; Fiellin, DA; Flanigan, TP; Lucas, GM; Mitty, J; Weiss, L; Woodson, T | 1 |
| Botsko, M; Egan, JE; Fiellin, DA; Finkelstein, R; Netherland, J; Weiss, L | 1 |
| Huxtable, CA; MacIntyre, PE; Roberts, LJ; Somogyi, AA | 1 |
| Chen, JS | 1 |
| Cockayne, L; McKeganey, N; Russell, C | 1 |
| Cerić, I; Mehić-Basara, N | 1 |
| Friedmann, PD; Schwartz, RP | 1 |
| Chavchanidze, M; Gamkrelidze, I; Nikolaishvili, N; Piralishvili, G | 2 |
| Ambrose-Lanci, LM; Ang, A; Berrettini, WH; Bruce, RD; Clarke, TK; Crist, RC; Hillhouse, MP; Ling, W; Lohoff, FW; Saxon, AJ; Woody, G | 1 |
| Ang, A; Baker, R; Canamar, CP; Hillhouse, MP; Ling, W; Marino, EN; Martin, JA; Nielsen, S; Potter, JS; Saxon, AJ; Wiest, K | 1 |
| Cohen, A; Hasson, A; Hillhouse, M; Hser, YI; Huang, D; Jacobs, P; Ling, W; McLaughlin, P; Saxon, AJ; Teruya, C; Thomas, C; Wiest, K | 1 |
| Furu, K; Karlstad, Ø; Selmer, R; Skurtveit, S | 1 |
| Hillemacher, T; Soyka, M | 1 |
| Bawor, M; Bonner, A; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Naji, L; Pare, G; Plater, C; Samaan, Z; Thabane, L; Varenbut, M; Worster, A | 1 |
| Adeniji, A; Elgadi, M; Huang, F; Joseph, D; Riesenberg, RR; Schobelock, MJ; Vince, BD; Webster, LR | 1 |
| Kamkamidze, G; Otiashvili, D; Piralishvili, G; Poole, S; Sikharulidze, Z; Woody, GE | 1 |
| Alho, H; Castrén, S; Lahti, T; Salonen, AH; Simojoki, K | 1 |
| Bruce, RD; Butterton, JR; Feng, HP; Hulskotte, EG; Lin, WH; O'Mara, E; Wagner, JA; Webster, LR; Xuan, F | 1 |
| Chalk, M; Lubran, R; Mark, TL; McCance-Katz, EF; Richardson, J | 1 |
| Alho, H; Kotovirta, E; Launonen, E; Simojoki, K; Wallace, I | 1 |
| Grunstein, RR; Haber, PS; Leung, S; Lintzeris, N; Wang, D; Yee, BJ | 1 |
| Bertz, R; Bifano, M; Bruce, RD; DeMicco, M; Garimella, T; Hwang, C; Kandoussi, H; Luo, WL; Wang, R; Wastall, P | 1 |
| Aden, B; Ang, A; Bray, JW; Eggman, AA; Hser, YI; Ling, W; Nosyk, B; Potter, J; Schackman, BR; Weiss, RD; Wittenberg, E | 1 |
| Björkman, P; Blomé, MA; Dahlman, D; Håkansson, A; Kral, AH | 1 |
| Carroll, KM; Evans, E; Hatch-Maillette, M; Hser, YI; Huang, D; Jelstrom, E; Ling, W; Liu, D; Matthews, AG; McLaughlin, P; Saxon, A; Wakim, P; Weiss, R; Wiest, K; Woody, G | 1 |
| Heikman, P; Ojanperä, I; Pelander, A; Sundström, M | 1 |
| Alati, R; Betts, KS; Burns, L; Chan, G; Dietze, P; McIlwraith, F; Whittaker, E | 1 |
| Altice, F; Barr, E; Chen, E; Conway, B; Dalgard, O; Dore, GJ; Dutko, FJ; Gane, EJ; Gendrano, IN; Grebely, J; Howe, AY; Huang, HC; Litwin, AH; Luetkemeyer, A; Nahass, R; Nguyen, BY; Nickle, DC; Peng, CY; Platt, HL; Robertson, MN; Shibolet, O; Wahl, J | 1 |
| Donroe, JH; Holt, SR; Tetrault, JM | 1 |
| Bramness, JG; Dalgard, O; Haukeland, JW; Midgard, H; Skurtveit, S | 1 |
| Brown, AM; Byford, S; Hellier, J; Kelleher, M; Kelly, J; Marsden, J; Mitcheson, L; Murphy, C; Shearer, J; Stillwell, G | 1 |
| Berrettini, WH; Crist, RC; Degenhardt, L; Doyle, GA; Ling, W; Martin, NG; Montgomery, GW; Nelson, EC; Saxon, AJ | 1 |
| Kahan, M; Nader, M; Srivastava, A | 1 |
| Pan, A; Zakowski, M | 1 |
| Gowing, L; Saulle, R; Vecchi, S | 1 |
| Coulton, S; Diaper, AM; Law, FD; Melichar, JK; Myles, JS; Nutt, DJ | 1 |
| Asatryan, A; Geoffroy, P; Kort, J; Kosloski, MP; Liu, W; Zhao, W | 1 |
| Lucas, P | 1 |
| McElrath, K | 1 |
| Hsu, CH; Wei, HT; Yeh, YH; Yu, KC | 1 |
| Aiyer, R; Bhatia, A; Gulati, A; Gungor, S; Mehta, N | 1 |
| Berrettini, WH; Crist, RC; Dechairo, BM; Doyle, GA; Gilbert, A; Li, J | 1 |
| Jones, HE; Kelly, AK; Lander, LR; Marshalek, PJ; Nguyen, L; O'Grady, KE; Schmidt, A | 1 |
| Cavallo, DA; Donroe, JH; Holt, SR; Tetrault, JM | 1 |
| Bjørnestad, R; Clausen, T; Muller, AE | 1 |
| Ahamad, K; Bruneau, J; Fischer, B; Jutras-Aswad, D; Le Foll, B; Lim, R; Socias, ME; Wild, TC; Wood, E | 1 |
| Evans, EA; Hser, YI; Kelleghan, A; Mooney, LJ; Saxon, AJ; Yoo, C; Zhu, Y | 1 |
| Fairbairn, N; Hayashi, K; Kerr, T; Lake, S; Liu, S; Milloy, MJ; Nolan, S; Shulha, HP; Socías, ME; Wood, E | 1 |
| Bozinoff, N; DeBeck, K; Fairbairn, N; Hayashi, K; Milloy, MJ; Nosova, E; Wood, E | 1 |
| Azar, P; Miles, I; Nikoo, M | 1 |
| Cibin, M; Lugoboni, F; Tamburin, S; Zamboni, L | 1 |
| Evans, EA; Hser, YI; Huang, D; Yoo, C; Zhu, Y | 1 |
| Ackerman, P; Chang, M; Llamoso, C; Lubin, S; Magee, M; Moore, K; Myers, E; Sevinsky, H | 1 |
| Jones, HE; Kraft, WK | 1 |
| Johnson, B; Richert, T | 1 |
| Hayden, KA; Marlinga, JC; Mrklas, KJ; Nixon, LL | 1 |
| Bertz, JW; Epstein, DH; Kowalczyk, WJ; Lin, JL; Mezghanni, M; Nunes, EV; Panlilio, LV; Phillips, KA; Preston, KL; Schroeder, JR; Stull, SW; Vahabzadeh, M | 1 |
| Chung, KS; Hsu, CY; Li, DJ; Lu, YS; Wu, HC | 1 |
| Evans, EA; Hser, YI; Huang, D; Saxon, AJ; Yoo, C | 1 |
| Ashford, RD; Bergman, BG; Kelly, JF | 1 |
| Grant, C; Hayashi, K; Kerr, T; Milloy, MJ; Weicker, SA; Wood, E | 1 |
| Homayra, F; Hongdilokkul, N; Krebs, E; Min, JE; Nosyk, B; Pearce, LA; Piske, M; Zhou, H | 1 |
| Han, KC; Hsu, CH; Huang, KY; Wei, HT; Yeh, YH; Yu, KC | 1 |
| Ali, R; Bruneau, J; Degenhardt, L; Fiellin, DA; Hickman, M; Jin, H; Larney, S; Marshall, BDL; Strang, J | 1 |
| Alcaraz, S; González-Saiz, F; Pérez de Los Cobos, J; Siñol, N; Trujols, J; Vergara-Moragues, E | 1 |
| Geddes, L; Iversen, J; Maher, L; Wand, H | 1 |
| Acevedo-Mackey, D; Acharjee, N; Akhtar, K; Al-Buriahi, MS; Amandi, A; An, Y; Anjum, NA; Asgari, Q; Badiei, B; Baez Vasquez, AY; Bagley, GD; Bahreini, MS; Bajelan, S; Baluja, MQ; Barbieri, MA; Batalha, MA; Bettiol, H; Bhattarai, U; Biset, JC; Bjerg, M; Björnsson, BT; Boag, AM; Borthwick, MS; Boukhris, I; Bragança, MLBM; Breves, JP; Britz-McKibbin, P; Broaddus, RR; Burnell, JE; Camargo, CA; Campo, M; Carlsen, KL; Catchpole, B; Cavalli, L; Chai, C; Chanakya, HN; Chang, AYH; Chantada, A; Chen, W; Chen, X; Chen, Y; Cheng, ZL; Chenoweth, DA; Chhetri, S; Coelho, CCNDS; Coker, ES; Cole, MA; Coniglio, A; Connor, TR; Corbishley, A; D'Arienzo, M; da Silva, AAM; Dai, Y; de Oliveira, BR; Dignac, MF; Dong, A; Dottino, JA; Duo, J; Einarsdottir, IE; Ekanayake, EMDNK; El Fels, L; El Hayany, B; El Shahawy, O; Elliott, RJR; Fabrizi, E; Farkas, K; Fellman, B; Fenoglio, D; Ferrario, M; Flögel, F; Fujiogi, M; Gamage, BD; Ganson, KT; Gao, X; Gärtner, S; Gautam, A; Gautam, S; Gaze, WH; Gosse, JA; Graham, DW; Graham, PA; Guastella, G; Guerrero, S; Gul, M; Guo, B; Guo, X; Gupta, VK; Hafidi, M; Halland, A; Han, W; Hardisty, M; Hasegawa, K; Hess, ST; Heydari, R; Hillary, LS; Holm, R; Huang, L; Jaleh, B; Jayasundara, JASB; Ji, X; Jiang, L; Jones, DL; Kac, G; Kebaili, I; Kelley, JB; Kelum, SHP; Kennedy, LJ; Khan, NA; Khazalpour, S; Khuntia, HK; Kinney, MS; Kommedal, Ø; Koomhin, P; Krawczyk, N; Kæstel, T; Lakmal, MAC; Li, H; Li, K; Li, R; Li, S; Li, W; Li, X; Li, Y; Liang, L; Lin, Y; Lippo, E; Liu, B; Liu, F; Liu, J; Liu, X; Liu, Y; Lodha, D; Loose, DS; López-Meza, P; Lu, F; Lu, KH; Lu, Y; Luo, Y; Ma, B; Malham, SK; Masood, A; Matan, N; McCormick, SD; McDonald, JE; McKenzie, LJ; Melendez, BD; Mikaeili, F; Mir, IR; Mirjalili, MH; Moreno, KP; Moura, IB; Müller, S; Nagata, JM; Nasri, A; Nasrollahzadeh, M; Navarro-Jiménez, E; Nie, E; Nielsen, CU; Nielsen, S; Nøhr, MK; Obeng, B; Odetayo, AA; Ortiz-Barrios, M; Ozgen, C; Pan, X; Parisi, ML; Paskavitz, AL; Patel, AK; Pedersen, M; Pontarollo, N; Potts, CM; Price, C; Pu, Y; Quénéa, K; Rahimi Khonakdari, M; Rather, BA; Raut, P; Regish, AM; Reible, DD; Rezadoost, H; Rizzati, M; Roviello, GN; Roviello, V; Rumpel, C; Sang, J; Sangroula, S; Saraiva, MDCP; Sarker, A; Sayyed, MI; Segoshi, A; Sehar, Z; Shao, X; Shaw, D; Shaw, L; Shekhawat, NS; Shim, JK; Shokouhimehr, M; Short, A; Soliman, PT; Songsamoe, S; Springer-Miller, RH; Stenstad, T; Strobl, E; Sun, R; Syme, H; Thai, L; Tian, G; Tofighi, B; Tonguc, B; Tuyiringire, D; Ulaganathan, N; Ulvestad, E; Varacca, A; Vergalli, S; Verma, DK; Villmones, HC; Wang, D; Wang, H; Wang, J; Wang, L; Wang, M; Wang, S; Wang, Y; Wang, Z; Weedon-Fekjær, H; Weller, SR; West, BE; Wilcox, MH; Wu, W; Wufuer, R; Xia, S; Xiang, H; Xu, H; Yan, L; Yang, RK; Yang, Y; Yates, MS; Ye, Q; Yin, H; Yin, Y; Yuan, Y; Yucesan, M; Yue, W; Zeng, W; Zhang, C; Zhang, D; Zhang, H; Zhang, L; Zhang, Q; Zhang, Y; Zhou, B; Zhou, Y; Zhu, Y; Zhu, Z | 1 |
| Bruneau, J; Greenland, S; Gustafson, P; Hongdilokkul, N; Karim, ME; Krebs, E; Maclure, M; McCandless, LC; Nosyk, B; Piske, M; Platt, RW; Siebert, U; Socías, ME; Thomson, T; Tsui, JI; Wood, E | 1 |
| Jia, L; Norman, WV | 1 |
| Rajput, K; Vadivelu, N | 1 |
| Chenworth, M; Graves, R; Hogg-Bremer, W; Love, JS; Perrone, J; Sarker, A | 1 |
| Evans, EA; Fei, Z; Hser, YI; Kelleghan, A; Matthews, A; Mooney, LJ; Saxon, AJ; Yoo, C; Zhu, Y | 1 |
| Curtis, ME; Evans, EA; Hser, YI; Kelleghan, A; Mooney, LJ; Saxon, AJ; Yoo, C; Zhu, Y | 1 |
| Berger, CA; Crocker, AM; Francis-Fath, S; Sobel, HG; Warrington, JS | 1 |
| Beauchamp, T; Derkzen, D; Farrell MacDonald, S; Fischer, B; Russell, C | 1 |
| Arias, F; Arnsten, J; Cunningham, CO; Olsen, JP; Rivera Mindt, M; Scott, TM | 1 |
| Assaf, C; Casado, MÁ; Flórez, G; Gómez, M; Gonzalvo, B; Muñoz, A; Notario, P; Oraa, R; Pascual, FS; Seijo, P | 1 |
| Arnold, R; Bulls, HW; Dao, E; Kapo, J; Khodyakov, D; King, C; Liebschutz, JM; Meier, D; Merlin, JS; Paice, J; Ritchie, C | 1 |
| Antoniou, T; Bozinoff, N; Campbell, T; Gomes, T; Mamdani, M; McCormack, D; Munro, C; Paterson, JM; Sproule, B; Tadrous, M | 1 |
| Antoniou, T; Bozinoff, N; Campbell, TJ; Gomes, T; Kitchen, SA; Men, S; Munro, C; Tadrous, M; Werb, D; Wyman, J | 1 |
| Antoniou, T; Bozinoff, N; Campbell, TJ; Garg, R; Gomes, T; Kitchen, SA; Men, S; Munro, C; Tadrous, M; Werb, D; Wyman, J | 1 |
| Ahamad, K; Brissette, S; Bruneau, J; Fikowski, J; Fischer, B; Gagnon, L; Jutras-Aswad, D; Le Foll, B; Ledjiar, O; Lim, R; Masse, B; Rehm, J; Socias, ME; Wild, TC; Wood, E | 1 |
| Bozinoff, N; Bruneau, J; Choi, JC; Hassan, A; Jutras-Aswad, D; Le Foll, B; Lim, R; Mok, WY; Rehm, J; Socias, ME; Wild, TC; Wood, E | 1 |
| Buxton, JA; DeBeck, K; Fast, D; Joe, R; Kwa, Y; Pilarinos, A; Thulien, M | 1 |
| Sadek, J; Saunders, J | 1 |
| Bastien, G; Brissette, S; Bruneau, J; Eugenia Socias, M; Foll, BL; Jutras-Aswad, D; Ledjiar, O; Lim, R; Marsan, S; McAnulty, C; Talbot, A | 1 |
| Dahan, A; Ellerbroek, H; Kramers, C; Schellekens, AFA; Timmerman, H; van den Heuvel, SAS | 1 |
| Díaz, I; Fishman, M; Goodwin, ATS; Luo, S; Nunes, EV; Rotrosen, J; Rudolph, KE; Shulman, M; Williams, NT | 1 |
| Saunders, EC | 1 |
| Bolton, J; Hoang, H; Laiteerapong, N; Marsh, J; Murugesan, M; Nocon, R; Peterson, L; Pollack, H | 1 |
| Bastien, G; Brissette, S; Hassan, AN; Jutras-Aswad, D; Le Foll, B; Ledjiar, O; Lim, R; Marsan, S; McAnulty, C; Socias, ME; Talbot, A | 1 |
| Díaz, I; Luo, SX; Nunes, EV; Rotrosen, J; Rudolph, KE; Williams, NT | 1 |
| Kahila, HK; Kanervo, MM; Nikkola, EM; Rantakari, KM; Tupola, SJ | 1 |
| Batki, SL; Baxley, C; Becker, W; Borsari, B; Herbst, E; Manuel, JK; Pennington, D; Reavis, JV; Seal, K | 1 |
| Chiu, K; McGee, M; Moineddin, R; Sud, A | 1 |
| Allen, E; Altobelli, G; Holmwood, C; Johnson, J; Samadian, S | 1 |
| Caputo, A; Christopher, C; Compton, P; Delgado, MK; Lowenstein, M; McFadden, R; Olenik, JM; Perrone, J; Ronning, K; Sigueza, AL; Thakrar, AP; Uritsky, TJ; Winston, A | 1 |
| Bakouni, H; Bastien, G; Brissette, S; Elkrief, L; Hébert, FO; Jutras-Aswad, D; Le Foll, B; Ledjiar, O; Lim, R; Marsan, S; McAnulty, C; Socias, ME | 1 |
| Enns, B; Jutras-Aswad, D; Krebs, E; Le Foll, B; Nosyk, B; Socias, ME; Whitehurst, DGT | 1 |
| Bozinoff, N; Cheol Choi, J; Eugenia Socias, M; Jutras-Aswad, D; Le Foll, B; Lim, R; Mocanu, V; Wood, E; Yin Mok, W | 1 |
| Brar, R; Choi, JC; Debeck, K; Eugenia Socias, M; Fairbairn, N; Hayashi, K; Johnson, C; Wilson, D | 1 |
| Ahamad, K; Bakouni, H; Foll, BL; Jutras-Aswad, D; Lim, R; McAnulty, C; Socias, ME; Tatar, O | 1 |
| Jaffe, K; Richardson, L | 1 |
12 review(s) available for methadone and buprenorphine, naloxone drug combination
| Article | Year |
|---|---|
Acute pain management in opioid-tolerant patients: a growing challenge.
Topics: Acute Disease; Analgesics; Analgesics, Opioid; Animals; Australia; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Tolerance; Humans; Hyperalgesia; Illicit Drugs; Methadone; Naloxone; Narcotic Antagonists; Narcotics; New Zealand; Opiate Substitution Treatment; Opioid-Related Disorders; Pain; Pain, Postoperative; Patient Discharge; Preoperative Care; Substance Withdrawal Syndrome | 2011 |
Short term health-related quality of life improvement during opioid agonist treatment.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Cost-Benefit Analysis; Female; Health Status; Heroin; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Quality of Life; Randomized Controlled Trials as Topic | 2015 |
Caring for patients with opioid use disorder in the hospital.
Topics: Acute Pain; Analgesics, Non-Narcotic; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Overdose; Hospitalization; Humans; Methadone; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Respiration, Artificial; Substance Withdrawal Syndrome | 2016 |
Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
Topics: Age Factors; Buprenorphine, Naloxone Drug Combination; Evidence-Based Medicine; Female; Health Status; Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders; Patient Preference; Primary Health Care; Risk Factors; Risk Reduction Behavior; Social Environment; Young Adult | 2017 |
Peripartum Anesthetic Management of the Opioid-tolerant or Buprenorphine/Suboxone-dependent Patient.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Peripartum Period; Pregnancy; Pregnancy Complications; Treatment Outcome | 2017 |
Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Directly Observed Therapy; Humans; Methadone; Observational Studies as Topic; Opiate Substitution Treatment; Opioid-Related Disorders; Prescription Drug Diversion; Randomized Controlled Trials as Topic | 2017 |
Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical Studies.
Topics: Administration, Buccal; Administration, Cutaneous; Administration, Sublingual; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Chronic Disease; Chronic Pain; Clinical Trials as Topic; Humans; Methadone; Neoplasms; Pain Management; Pain Measurement; Risk; Treatment Outcome | 2018 |
Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome.
Topics: Analgesia, Obstetrical; Analgesics; Analgesics, Opioid; Breast Feeding; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Clonidine; Female; Humans; Hypnotics and Sedatives; Infant, Newborn; Kangaroo-Mother Care Method; Maternal-Fetal Exchange; Methadone; Neonatal Abstinence Syndrome; Occupational Therapy; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Management; Patient Education as Topic; Phenobarbital; Physical Therapy Modalities; Pregnancy; Pregnancy Complications; Rooming-in Care | 2019 |
Global opioid agonist treatment: a review of clinical practices by country.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Topics: Acyclic Monoterpenes; Adipose Tissue; Adolescent; Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollutants, Occupational; Amino Acid Transport Systems; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Arthrobacter; Bacteria; Bacteriological Techniques; Benzaldehydes; Biodegradation, Environmental; Biofilms; Biological Transport; Biomarkers; Biomass; Bioreactors; Body Composition; Body Mass Index; Brassica; Brazil; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Caco-2 Cells; Cadmium; Calcium; Calcium Carbonate; Calcium Channels; Catalysis; Cell Degranulation; Cell Line; Cell Membrane; Chitosan; Chromatography, High Pressure Liquid; Chromium; Cobalt; Cohort Studies; Colony Count, Microbial; Composting; Copper; COVID-19; Cross-Sectional Studies; Cytoplasm; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Diethylhexyl Phthalate; Dose-Response Relationship, Drug; Drug Implants; Drug Stability; Drug Synergism; Electroplating; Endometrial Neoplasms; Endometrium; Environmental Monitoring; Environmental Restoration and Remediation; Estradiol; Estrogens; Feces; Female; Food Microbiology; Food Preservation; Fruit and Vegetable Juices; Gasotransmitters; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gene Expression Regulation, Developmental; Genetic Predisposition to Disease; Glutathione; Gold; Graphite; Growth Hormone; Harm Reduction; Hot Temperature; Humans; Hydrocortisone; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydrogen-Ion Concentration; Ileum; Imidazoles; Injections, Intraperitoneal; Insecticides; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor I; Intestinal Absorption; Light; Lignin; Liver; Magnetics; Male; Manganese; Mast Cells; Melanoma; Membrane Potentials; Metals; Methadone; Microbial Viability; Microplastics; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Middle Aged; Mitochondrial Swelling; Molecular Dynamics Simulation; Monophenol Monooxygenase; Morocco; Naloxone; Naltrexone; Nanocomposites; Nanomedicine; Nanoparticles; Narcotic Antagonists; Neonicotinoids; Nitric Oxide; Nitro Compounds; Nitrogen; Nitrogen Compounds; Obesity; Obesity, Abdominal; Occupational Exposure; Ontario; Opiate Substitution Treatment; Opioid-Related Disorders; Oryza; Overweight; Oxidative Stress; Oxides; Oxygen; Perception; Photoelectron Spectroscopy; Plants; Plastics; Point Mutation; Polychlorinated Biphenyls; Polycyclic Aromatic Hydrocarbons; Potassium; Premenopause; Prodrugs; Prospective Studies; Protons; Pyrolysis; Qualitative Research; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Resins, Synthetic; Rhodamines; Risk Factors; ROC Curve; Salmo salar; SARS-CoV-2; Seawater; Severity of Illness Index; Sewage; Social Media; Soil; Soil Microbiology; Soil Pollutants; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Staining and Labeling; Stainless Steel; Steel; Stress, Physiological; Substance Abuse Treatment Centers; Symporters; T-Lymphocytes; Toluene; Triclosan; Ultraviolet Rays; Waist Circumference; Waste Disposal, Fluid; Wastewater; Water Purification; Welding; X-Ray Diffraction; Young Adult | 2020 |
Acute Pain Management of Chronic Pain Patients in Ambulatory Surgery Centers.
Topics: Acute Pain; Analgesics, Opioid; Anesthesia, Conduction; Buprenorphine, Naloxone Drug Combination; Chronic Pain; Drug Tolerance; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain, Postoperative; Perioperative Care; Surgicenters | 2021 |
Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Craving; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2023 |
30 trial(s) available for methadone and buprenorphine, naloxone drug combination
| Article | Year |
|---|---|
Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment.
Topics: Anti-Retroviral Agents; Buprenorphine; Buprenorphine, Naloxone Drug Combination; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Male; Mental Disorders; Methadone; Middle Aged; Naloxone; Narcotic Antagonists; Narcotics; Prisoners; Substance-Related Disorders | 2010 |
The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment.
Topics: Ambulatory Care; Buprenorphine; Buprenorphine, Naloxone Drug Combination; HIV Infections; Humans; Methadone; Multicenter Studies as Topic; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pilot Projects; United States | 2011 |
Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
Topics: Adult; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Follow-Up Studies; Health Policy; Heroin Dependence; Humans; Male; Methadone; Naloxone; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Time Factors; Treatment Outcome; United Kingdom | 2013 |
An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.
Topics: Adult; Analgesics, Opioid; Black or African American; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Genotype; Humans; Introns; Male; Methadone; Middle Aged; Naloxone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Polymorphism, Single Nucleotide; Receptors, Opioid, delta; Treatment Outcome; White People | 2013 |
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
Topics: Adult; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Heroin Dependence; Humans; Male; Methadone; Middle Aged; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Severity of Illness Index; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2013 |
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male; Medication Adherence; Methadone; Middle Aged; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome; Young Adult | 2014 |
Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy.
Topics: Administration, Oral; Adult; Aminoisobutyric Acids; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Interactions; Female; Humans; Leucine; Male; Methadone; Middle Aged; Oligopeptides; Proline; Quinolines; Substance Withdrawal Syndrome; Substance-Related Disorders; Thiazoles; Young Adult | 2015 |
Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
Topics: Adult; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Counseling; Drug Users; Female; Georgia (Republic); Humans; Methadone; Middle Aged; Naloxone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Abuse, Intravenous; Treatment Outcome | 2015 |
Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy.
Topics: Adolescent; Adult; Aged; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Interactions; Female; Humans; Maintenance Chemotherapy; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Proline; Protease Inhibitors; Young Adult | 2015 |
Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Random Allocation; Treatment Outcome; Young Adult | 2016 |
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzofurans; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; Medication Adherence; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Quinoxalines; Recurrence; Substance Abuse, Intravenous; Young Adult | 2016 |
Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: Study protocol for a pragmatic randomised controlled trial.
Topics: Adaptation, Psychological; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Methadone; Motivation; Opiate Substitution Treatment; Opioid-Related Disorders; Social Support; United Kingdom | 2017 |
Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Clonidine; Craving; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methadone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2017 |
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Methadone; Middle Aged; Naloxone; Opiate Substitution Treatment; Opioid-Related Disorders; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides; Surveys and Questionnaires; Young Adult | 2017 |
The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Topics: Adult; Analgesics, Opioid; Behavior Observation Techniques; Buprenorphine, Naloxone Drug Combination; Canada; Drug Administration Schedule; Female; Humans; Male; Methadone; Narcotic Antagonists; Needs Assessment; Opiate Substitution Treatment; Opioid-Related Disorders; Prescription Drug Overuse; Substance Abuse Detection | 2018 |
Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Time Factors; Young Adult | 2018 |
Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; California; Criminal Law; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Narcotic Antagonists; Opioid-Related Disorders; Patient Outcome Assessment | 2019 |
Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Topics: Adult; Anti-HIV Agents; Buprenorphine, Naloxone Drug Combination; Cross-Over Studies; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Methadone; Middle Aged; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Organophosphates; Piperazines; Young Adult | 2019 |
Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.
Topics: Adolescent; Adult; Aged; Buprenorphine, Naloxone Drug Combination; Female; Follow-Up Studies; Health Services Accessibility; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Acceptance of Health Care; Prospective Studies; Young Adult | 2019 |
Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Follow-Up Studies; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Comorbidity; Depressive Disorder, Major; Follow-Up Studies; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome | 2021 |
Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Drug Overdose; Female; Humans; Male; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions | 2022 |
Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Female; Fentanyl; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions | 2022 |
Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Craving; Humans; Methadone; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions | 2022 |
Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Chronic Pain; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions; Quality of Life; Randomized Controlled Trials as Topic | 2022 |
Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Depression; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions | 2023 |
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study.
Topics: Analgesics, Opioid; Bayes Theorem; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cannabis; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2023 |
Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cost-Benefit Analysis; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions | 2023 |
Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions | 2023 |
Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Heroin; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions | 2023 |
66 other study(ies) available for methadone and buprenorphine, naloxone drug combination
| Article | Year |
|---|---|
[Heroin substitution treatments. Analysis of current solutions, trends, and perspectives].
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Combinations; Humans; Methadone; Naloxone; Narcotics; Opioid-Related Disorders | 2006 |
Treatment of acute pain in opioid tolerant patients.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Tolerance; Humans; Methadone; Naloxone; Opioid-Related Disorders; Pain; Pain Measurement | 2010 |
The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
Topics: Administration, Inhalation; Administration, Intranasal; Adult; Age Factors; Analgesics, Opioid; Australia; Behavior, Addictive; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Drug Users; Female; Humans; Interviews as Topic; Logistic Models; Male; Methadone; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prevalence; Prisons; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Smoking; Substance Abuse Treatment Centers | 2011 |
Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Methadone; Middle Aged; Naloxone; Narcotic Antagonists; Needle Sharing; Odds Ratio; Opiate Substitution Treatment; Opioid-Related Disorders; Risk-Taking; Unsafe Sex | 2011 |
Studying up harm reduction policy: the office as an assemblage.
Topics: Administrative Personnel; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug and Narcotic Control; Drug Users; Government Regulation; Harm Reduction; Health Policy; HIV Infections; Humans; Incidence; Methadone; Naloxone; Needle-Exchange Programs; Opiate Substitution Treatment; Policy Making; Private Sector; Qualitative Research; Social Behavior; Speech; Substance Abuse, Intravenous; Taiwan | 2011 |
Treatment of addicts in Bosnia and Herzegovina--constraints and opportunities.
Topics: Adult; Analgesics, Opioid; Bosnia and Herzegovina; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Community Mental Health Centers; Humans; Mental Health Services; Methadone; Naloxone; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome | 2012 |
Just call it "treatment".
Topics: Behavior, Addictive; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Counseling; Humans; Methadone; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance-Related Disorders | 2012 |
Evaluation of the quality of life (Whoqol-Bref) among methadone and suboxone substitution state program patients and healthy volunteers in Georgia.
Topics: Adult; Aged; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Case-Control Studies; Female; Georgia (Republic); Government Programs; Humans; Male; Methadone; Middle Aged; Naloxone; Opiate Substitution Treatment; Quality of Life; Social Change; Surveys and Questionnaires; Young Adult | 2012 |
Needs assessment and treatment compliance at state opioid substitution treatment programes in Georgia.
Topics: Adult; Aged; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Georgia (Republic); Government Programs; Heroin Dependence; Humans; Hypnotics and Sedatives; Male; Marijuana Abuse; Methadone; Middle Aged; Naloxone; Needs Assessment; Opiate Substitution Treatment; Patient Compliance; Patient Satisfaction; Psychotherapy; Substance-Related Disorders; Surveys and Questionnaires; Young Adult | 2013 |
Prescribing of drugs for attention-deficit hyperactivity disorder in opioid maintenance treatment patients in Norway.
Topics: Adolescent; Adult; Analgesics, Opioid; Attention Deficit Disorder with Hyperactivity; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Central Nervous System Stimulants; Databases, Factual; Female; Humans; Male; Methadone; Naloxone; Norway; Opiate Substitution Treatment; Opioid-Related Disorders; Prescription Drugs; Treatment Outcome; Young Adult | 2014 |
Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male; Medication Adherence; Methadone; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2014 |
The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Heroin; Humans; Methadone; Naloxone; Naltrexone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Research Design; Systematic Reviews as Topic | 2014 |
Past-year gambling behaviour among patients receiving opioid substitution treatment.
Topics: Adult; Age Factors; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Drug Combinations; Female; Finland; Gambling; Humans; Male; Methadone; Middle Aged; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Sex Factors | 2015 |
Medicaid coverage of medications to treat alcohol and opioid dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Buprenorphine, Naloxone Drug Combination; Humans; Insurance Coverage; Medicaid; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Taurine; United States | 2015 |
Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Female; Finland; Humans; Male; Methadone; Middle Aged; Multivariate Analysis; Opiate Substitution Treatment; Opioid-Related Disorders; Prescription Drug Diversion; Regression Analysis; Surveys and Questionnaires; Young Adult | 2015 |
Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report.
Topics: Buprenorphine, Naloxone Drug Combination; Heroin Dependence; Humans; Hypoxia; Male; Methadone; Middle Aged; Polysomnography; Respiration; Sleep; Sleep Apnea, Central | 2015 |
Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Carbamates; Drug Interactions; Imidazoles; Methadone; Pyrrolidines; Valine | 2015 |
Correlates of Skin and Soft Tissue Infections in Injection Drug Users in a Syringe-Exchange Program in Malmö, Sweden.
Topics: Adult; Amphetamine-Related Disorders; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Users; Female; Heroin Dependence; Housing; Humans; Ill-Housed Persons; Logistic Models; Male; Methadone; Methylphenidate; Middle Aged; Neck; Needle-Exchange Programs; Odds Ratio; Opioid-Related Disorders; Prescription Drugs; Prevalence; Sex Factors; Skin Diseases, Bacterial; Soft Tissue Infections; Substance Abuse, Intravenous; Surveys and Questionnaires; Sweden; Young Adult | 2015 |
New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Chromatography, Liquid; Female; Humans; Illicit Drugs; Male; Mass Spectrometry; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Psychotropic Drugs; Retrospective Studies; Substance Abuse Detection; Substance-Related Disorders; Young Adult | 2016 |
Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies.
Topics: Abscess; Adolescent; Adult; Alcoholism; Amphetamine-Related Disorders; Analgesics, Opioid; Australia; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cocaine-Related Disorders; Cross-Sectional Studies; Drug Overdose; Female; Heroin Dependence; Humans; Male; Marijuana Abuse; Methadone; Middle Aged; Needle Sharing; Odds Ratio; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Abuse, Intravenous; Substance-Related Disorders; Thrombosis; Violence; Young Adult | 2016 |
Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.
Topics: Adult; Antipsychotic Agents; Antiviral Agents; Benzodiazepines; Buprenorphine, Naloxone Drug Combination; Disease Notification; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Methadone; Middle Aged; Norway; Opiate Substitution Treatment; Polyethylene Glycols; Recombinant Proteins; Registries; Ribavirin; Selective Serotonin Reuptake Inhibitors; Substance Abuse, Intravenous | 2016 |
A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence.
Topics: 3' Untranslated Regions; Adult; Alleles; Analgesics, Opioid; Australia; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Genotype; Humans; Male; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Polymorphism, Genetic; Receptors, Opioid, mu; White People | 2018 |
Rationale for cannabis-based interventions in the opioid overdose crisis.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Drug Overdose; Evidence-Based Medicine; Harm Reduction; Humans; Medical Marijuana; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Public Health; Public Policy | 2017 |
Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Health Services Accessibility; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Compliance; Social Control, Formal; Social Stigma | 2018 |
Traditional Chinese medicine-facilitated treatments may relieve anxiety symptoms during drug switching from methadone to buprenorphine/naloxone for treating opioid dependence.
Topics: Anxiety; Buprenorphine, Naloxone Drug Combination; Drug Substitution; Drugs, Chinese Herbal; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders | 2017 |
Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Female; Genotype; Humans; Male; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Dropouts; Pharmacogenetics; Pharmacogenomic Testing; Treatment Outcome | 2018 |
Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure.
Topics: Adult; Appalachian Region; Birth Weight; Buprenorphine, Naloxone Drug Combination; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Pregnant Women; Retrospective Studies; Risk Adjustment | 2018 |
Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder.
Topics: Adult; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cocaine-Related Disorders; Drug Contamination; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Substance Abuse Detection | 2018 |
Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; Maintenance Chemotherapy; Male; Methadone; Middle Aged; Norway; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Dropouts; Patient Satisfaction; Surveys and Questionnaires | 2018 |
High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Topics: Adult; Analgesics, Opioid; British Columbia; Buprenorphine, Naloxone Drug Combination; Female; Humans; Longitudinal Studies; Male; Marijuana Use; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Retention in Care | 2018 |
Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Canada; Case-Control Studies; Drug Overdose; Female; Humans; Male; Medication Adherence; Methadone; Opioid-Related Disorders; Prevalence; Prisoners; Prospective Studies | 2018 |
Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Fentanyl; Humans; Inpatients; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2018 |
Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
Topics: Administration, Intravenous; Adolescent; Adult; Analgesics, Opioid; Benzodiazepines; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Drug Misuse; Female; Hospitalization; Humans; Italy; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Risk Factors; Young Adult | 2019 |
Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cities; Drug Trafficking; Female; Humans; Male; Methadone; Motivation; Opiate Substitution Treatment; Opioid-Related Disorders; Prescription Drug Diversion; Prevalence; Self Medication; Substance Withdrawal Syndrome; Sweden | 2019 |
Barriers and facilitators to office-based opioid agonist therapy prescribing and effective interventions to increase provider prescribing: protocol for a systematic review.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Physicians, Family; Practice Patterns, Physicians'; Primary Health Care; Systematic Reviews as Topic | 2019 |
Stress, craving and mood as predictors of early dropout from opioid agonist therapy.
Topics: Adult; Affect; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Craving; Ecological Momentary Assessment; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Dropouts; Stress, Psychological; Withholding Treatment | 2019 |
Factors impeding switching from methadone to buprenorphine in heroin users receiving methadone maintenance therapy - A naturalistic cohort study.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Comorbidity; Female; Heroin Dependence; Humans; Male; Methadone; Opiate Substitution Treatment; Retrospective Studies; Taiwan | 2019 |
Attitudes toward opioid use disorder medications: Results from a U.S. national study of individuals who resolved a substance use problem.
Topics: Adolescent; Adult; Attitude; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prevalence; United States; Young Adult | 2020 |
Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
Topics: Adult; Analgesics, Opioid; British Columbia; Buprenorphine, Naloxone Drug Combination; Cohort Studies; Female; Humans; Male; Methadone; Middle Aged; Narcotic Antagonists; Opioid-Related Disorders; Patient Acceptance of Health Care; Prospective Studies | 2019 |
Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia.
Topics: Adult; Age Factors; British Columbia; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Acceptance of Health Care; Practice Patterns, Physicians'; Retrospective Studies; Sex Factors; Young Adult | 2020 |
Traditional Chinese Medicine-facilitated switch from methadone to buprenorphine-naloxone for treatment of heroin dependence: a case report.
Topics: Buprenorphine, Naloxone Drug Combination; Heroin Dependence; Humans; Male; Medicine, Chinese Traditional; Methadone; Middle Aged; Treatment Outcome | 2019 |
Towards a common metric for assessing heroin-dependent patient satisfaction with medications: Testing methadone and buprenorphine-naloxone.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Heroin; Heroin Dependence; Humans; Male; Methadone; Patient Satisfaction; Spain | 2020 |
Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Humans; Incidence; Infant, Newborn; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Abuse, Intravenous | 2021 |
Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.
Topics: Adult; Analgesics, Opioid; British Columbia; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Observational Studies as Topic; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies | 2020 |
Contraception Practices Among Women on Opioid Agonist Therapy.
Topics: Adult; British Columbia; Buprenorphine, Naloxone Drug Combination; Contraception; Contraception Behavior; Cross-Sectional Studies; Family Planning Services; Female; Health Services Accessibility; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy, Unplanned; Substance-Related Disorders | 2021 |
Methadone and suboxone
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Narcotic Antagonists; Natural Language Processing; Opiate Substitution Treatment; Opioid-Related Disorders; Public Opinion; Social Media | 2021 |
A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care | 2021 |
Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies | 2022 |
Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Humans; Longitudinal Studies; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Pilot Projects | 2021 |
Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Perception; Retrospective Studies | 2022 |
Expert Panel Consensus on Management of Advanced Cancer-Related Pain in Individuals With Opioid Use Disorder.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Cancer Pain; Delphi Technique; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Prognosis; Qualitative Research | 2021 |
Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cohort Studies; Drug Overdose; Humans; Methadone; Ontario; Opiate Overdose; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; COVID-19; Humans; Methadone; Ontario; Opiate Substitution Treatment; Opioid-Related Disorders; Pandemics | 2022 |
Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; COVID-19; Humans; Methadone; Ontario; Opiate Substitution Treatment; Opioid-Related Disorders; Pandemics; Prevalence; Time Factors | 2022 |
Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Canada; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies | 2022 |
Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence | 2022 |
Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions | 2022 |
Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Delivery of Health Care; Humans; Medicaid; Methadone; Naltrexone; Opioid-Related Disorders; Primary Health Care; United States | 2022 |
Optimally Choosing Medication Type for Patients With Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; Illicit Drugs; Infant, Newborn; Methadone; Mothers; Opioid-Related Disorders; Parturition; Pregnancy; Pregnancy Complications | 2023 |
The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment.
Topics: Buprenorphine, Naloxone Drug Combination; Canada; Costs and Cost Analysis; Drugs, Generic; Humans; Insurance Claim Review; Marketing; Methadone; Opioid-Related Disorders | 2023 |
Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.
Topics: Analgesics, Opioid; Australia; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Outcome Assessment; Patient Satisfaction | 2023 |
Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; Hydromorphone; Male; Methadone; Naloxone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain | 2023 |
Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
Topics: Analgesics, Opioid; British Columbia; Buprenorphine; Buprenorphine, Naloxone Drug Combination; COVID-19; Humans; Interrupted Time Series Analysis; Methadone; Morphine Derivatives; Opiate Substitution Treatment; Opioid-Related Disorders; Pandemics | 2023 |
"I thought it was for guys that did needles": Medication perceptions and lay expertise among medical research participants.
Topics: British Columbia; Buprenorphine, Naloxone Drug Combination; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |